James F Emigh insider trades: Acura Pharmaceuticals (ACUR) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where James reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 14, 2017 | ACUR | ↑ Buy | 400,000 | $0.10 | $40K | Direct | Dec 18, 2017 (4d) |
| May 16, 2014 | ACUR | ↑ Buy | 15,000 | $1.21 | $18K | Direct | May 19, 2014 (3d) |
| Aug 12, 2011 | ACUR | ↑ Buy | 5,000 | $2.60 | $13K | Direct | Aug 15, 2011 (3d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About James F Emigh's insider trades
James F Emigh is VP, Corporate Development at Acura Pharmaceuticals (ACUR). Since Aug 12, 2011, James has reported 3 open-market purchases worth $71K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (12 filings), option exercises (7 filings), shares withheld for taxes (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ACUR insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.